Esperion shows real top-line growth but is weighed down by a consecutive earnings-miss streak, falling forward estimates, net insider selling, and a risk/reward setup that has already failed the engine's asymmetry gate.
Thesis pillars
- Revenue Growth Despite Losses→Stable
- Consecutive Earnings Misses→Stable
- Estimates Trending Down→Stable
- +2 more pillars — see the Why tab for full reasoning
Esperion Therapeutics, Inc. (ESPR) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $3.19, A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: two products (bempedoic acid, bempedoic acid/ezetimibe tablet); Concentration risk — Supplier: sole source third-party manufacturers.
Esperion Therapeutics is a commercial-stage biopharmaceutical company that markets NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe), FDA-approved oral, non-statin medicines that lower LDL cholesterol and reduce cardiovascular risk. The company generated $159.6... Read more
Sell if holding. At $3.19, A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: two products (bempedoic acid, bempedoic acid/ezetimibe tablet); Concentration risk — Supplier: sole source third-party manufacturers. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 28d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Esperion Therapeutics, Inc.
About Esperion Therapeutics, Inc.
Esperion Therapeutics markets NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe), FDA-approved oral non-statin therapies for cardiovascular risk reduction, generating $159.6 million in net U.S. product revenue in 2025. International sales flow through partners Daiichi Sankyo Europe, Otsuka in Japan, and HLS Therapeutics in Canada, with expanded indications approved in the U.S., EU, and UK since March 2024.
Esperion earns nearly all of its revenue from prescription sales of the bempedoic acid franchise to patients with established or high-risk cardiovascular disease who cannot tolerate statins, distributed largely through U.S. specialty and retail pharmacy channels with reimbursement subject to prior-authorization requirements the company supports with a dedicated assistance program. Ex-U.S. commercialization runs through licensing partners who market the combination as NILEMDO and NUSTENDI across Europe and territories in Asia, generating royalty and milestone income rather than direct sales. The company does not own manufacturing facilities and depends on sole source third-party suppliers to produce both bempedoic acid and the combination tablet, while the combination product also depends on continued market availability of ezetimibe from outside producers. Beyond the approved franchise, Esperion is advancing a preclinical pipeline of next-generation ACLY inhibitors targeting primary sclerosing cholangitis.
Show full overview
Esperion's near-term risk concentrates in its supply chain rather than its clinical pipeline: the 10-K discloses that the company may rely on sole source third-party suppliers to manufacture bempedoic acid and the combination tablet, with no guaranteed minimum production commitments from those manufacturers. The ezetimibe component compounds this exposure, since outside producers are under no obligation to maintain current output or continue making the ingredient available at all. Because the company depends almost entirely on these two products for revenue, a manufacturing disruption at either supplier could directly impair commercial supply rather than merely delay a pipeline readout.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Esperion Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Esperion Therapeutics, Inc.
Latest news
- NEWS 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga Jul 1, 2026 neutral
Generated 2026-07-08T23:03:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProducttwo products (bempedoic acid, bempedoic acid/ezetimibe tablet)10-K Item 1A: 'We depend almost entirely on the success of two products, bempedoic acid and the bempedoic acid / ezetimibe combination tablet.'
- HIGHSuppliersole source third-party manufacturers10-K Item 1A: 'We may rely on sole source third-party suppliers to manufacture and supply bempedoic acid, the bempedoic acid / ezetimibe combination tablet'
- MEDIUMSupplierezetimibe supply10-K Item 1A: 'is dependent on the continued availability of ezetimibe in the marketplace, and there can be no assurance that the current availability of ezetimibe will continue'
Material Events(8-K, last 90d)
- 2026-06-01Item 5.02LOWAt the May 28, 2026 annual meeting, stockholders approved an amendment to the 2022 Stock Option and Incentive Plan increasing shares authorized for issuance by 7,000,000. Routine equity-plan governance action; no officer or director departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $3.19, A.R:R is negative (-1.0) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: two products (bempedoic acid, bempedoic acid/ezetimibe tablet); Concentration risk — Supplier: sole source third-party manufacturers. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.15. Score 5.7/10, moderate confidence.
Take-profit target: $3.67 (+15.0% upside). Prior stop was $3.15. Stop-loss: $3.15.
Concentration risk — Product: two products (bempedoic acid, bempedoic acid/ezetimibe tablet); Concentration risk — Supplier: sole source third-party manufacturers; Analyst target reached - limited upside remaining.
Esperion Therapeutics, Inc. trades at a P/E of N/A (forward 10.8). TrendMatrix value score: 6.0/10. Verdict: Sell.
11 analysts cover ESPR with a consensus score of 2.5/5. Average price target: $3.
What does Esperion Therapeutics, Inc. do?Esperion Therapeutics is a commercial-stage biopharmaceutical company that markets NEXLETOL (bempedoic acid) and...
Esperion Therapeutics is a commercial-stage biopharmaceutical company that markets NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe), FDA-approved oral, non-statin medicines that lower LDL cholesterol and reduce cardiovascular risk. The company generated $159.6 million in net U.S. product revenue in 2025, with international sales through partners including Daiichi Sankyo Europe, Otsuka in Japan, and HLS Therapeutics in Canada. Esperion depends almost entirely on this two-product franchise and does not own manufacturing facilities, relying on sole-source third-party suppliers.